A new randomized, double-blind, placebo controlled trial has found that Lonza’s proprietary arabinogalactan-based immune support ingredient, ResistAid, increases antibody response in healthy adults after exposure to the Tetanus vaccine. Conducted at a dosage of 1.5 g/day, the study found the efficacy of ResistAid at a significantly lower dosage, as compared to the 4.5 g/day that was previously found to be effective. The findings were published in the October issue of Journal of the American College of Nutrition.
 
Subjects included 75 healthy adults (18-61 years old) who were randomized to receive either 1.5 g/day or 4.5 g/day of ResistAid or placebo for 60 days. At day 30, subjects were administered both Tetanus and Influenza vaccines. Serum antigenic response (Tetanus IgG, Influenza A and B IgG and IgM) were measured at days 45 (15 days after vaccination) and 60 (30 days after vaccination) of the study and compared to baseline antibody levels. As expected, all three groups demonstrated a rise in Tetanus IgG levels 15 and 30 days following the vaccine. There was a significant difference in the rise in Tetanus IgG levels at day 60 in the 1.5 g/day group compared to placebo (p = 0.008). Neither group demonstrated any significant elevations in IgM or IgG antibodies compared to placebo following the Influenza vaccine.
 
For more information: www.lonza.com